CTLA4 and non-small cell lung carcinoma: Several cost-effectiveness studies on PD-(L)1 plus chemotherapy plus CTLA-4 blockade as a first-line therapy for NSCLC have been conducted (Peng et al., 2021; Polyzoi et al., 2022), with the aim of combining the persistence of combined immunotherapy with the initial beneficial effect of chemotherapy.